OC-MO-001
8:00 AM - 8:15 AM
MICROALBUMINURIA: A NOVEL RISK MARKER FOR VENOUS THROMBOEMBOLISM
B. K. Mahmoodi* (NL), R. Gansevoort, N. Veeger, A. Matthews, G. Navis, H. Hillege, J. van der Meer

OC-MO-002
8:15 AM - 8:30 AM
UNIQUE WHOLE BLOOD GENE EXPRESSION PROFILES DISTINQUISH DIFFERENT CLINICAL PHENOTYPES OF VENOUS THROMBOEMBOLISM
D. A. Lewis* (US), G. Stashenko, O. M. Akay, L. Price, A. Metjian, J. Chi, T. L. Ortel

OC-MO-003
8:30 AM - 8:45 AM
FACTOR Xa GENERATION IN ADULT INDIVIDUALS K. Brummel-Ziedins* (US),
T. Ashikaga, T. Orfeo, M. Gissel, K. G. Mann, F. R. Rosendaal

OC-MO-004
8:45 AM - 9:00 AM
PROS1 GENE DELETIONS ARE RARE IN A POPULATION-BASED STUDY ON VENOUS THROMBOSIS
M. C. Pintao* (NL), A. A. Garcia, M. C. H. de Visser, C. J. M. Doggen, P. H. Reitsma, F. R. Rosendaal

OC-MO-005
9:00 AM - 9:15 AM
TYPE III PROTEIN S DEFICIENCY IS ASSOCIATED WITH A HYPERCOAGULABLE STATE AND AN INCREASED RISK OF VENOUS THROMBOSIS
E. Castoldi* (NL), L. F. Maurissen, D. Tormene, L. Spiezia, S. Gavasso, C. Radu, T. M. Hackeng, J. Rosing, P. Simioni

OC-MO-006
9:15 AM - 9:30 AM
HETEROGENEOUS PRESENTATION OF FV IN FV LEIDEN HETEROZYGOTES
M. F. Whelihan* (US), M. Cushman, K. G. Mann

Chairpersons: Koneti Rao (US) and Carlo Patrono (IT)

OC-MO-007
8:00 AM - 8:15 AM
IMPACT OF THE CYP2C19*17 ALLELE ON PLATELET RESPONSE TO CLOPIDOGREL IN PATIENTS SUFFERING FROM NON–ST ELEVATION ACUTE CORONARY SYNDROME
C. Frere* (FR), T. Cuisset, P. Morange, L. Camoin-Jau, J. Bonnet, M. Alessi, J. Hulot

OC-MO-008
8:15 AM - 8:30 AM
THE RELATIVE CONTRIBUTION OF THE CYP2C19*2 POLYMORPHISM IN THE LOW RESPONSIVENESS TO CLOPIDOGREL IN THE VASP02 STUDY
B. Aleil, L. Jacquemin, F. de Poli, M. Zaehringer, J. P. Collet, G. Montalescot, C. Léon, J. P. Cazenave, M. C. Dickele, J. P. Monassier, C. Gachet* (FR)

OC-MO-009
8:30 AM - 8:45 AM
LONG TERM PROGNOSTIC VALUE OF ASPIRIN NON-RESPONSIVENESS AND PLATELET REACTIVITY AFTER ACUTE VASCULAR EVENTS: A POPULATION-BASE COHORT STUDY
P. Harrison* (UK), L. Silver, H. Segal, A. Syed, Z. Mehta, P. Rothwell

OC-MO-010
8:45 AM - 9:00 AM
CYTOCHROME P450 2C19 POLYMORPHISM AND CARDIOVASCULAR RECURRENCES IN PATIENTS UNDER CLOPIDOGREL TREATMENT: A META-ANALYSIS
F. Sofi* (IT), B. Giusti, A. Gori, R. Marcucci, R. Abbate, G. Gensini

OC-MO-011
9:00 AM - 9:15 AM
DIFFERENTIAL SENSITIVITY OF THE VARIOUS EX VIVO TESTS MONITORING FUNCTIONAL VARIABILITY OF PLATELET RESPONSE TO CLOPIDOGREL
C. Bal Dit Sollier, N. Berge, B. Boval, L. Drouet* (FR)

OC-MO-012
9:15 AM - 9:30 AM
RIFAMPICIN INCREASES THE EXTENT OF P2Y12 RECEPTOR BLOCKADE ACHIEVED BY CLOPIDOGREL ADMINISTRATION
S. B. G. Patil* (UK), H. M. Judge, R. J. Buckland, J. A. Jakubowski, R. F. Storey

Chairpersons: Paolo Simioni (IT) and Agnes Lee (CA)

OC-MO-013
8:00 AM - 8:15 AM
WHAT IS THE LONG-TERM RISK FOR NEW CANCER IN PATIENTS WITH A FIRST EPISODE OF VENOUS THROMBOEMBOLISM?
J. Douketis* (CA), C. Gu, A. Piccioli, A. Ghirarduzzi, V. Pengo, P. Prandoni

OC-MO-014
8:15 AM - 8:30 AM
SCREENING FOR MALIGNANCY IN PATIENTS WITH IDIOPATHIC
VENOUS THROMBOSIS. THE TROUSSEAU INVESTIGATORS
F. F. van Doormaal* (NL), J. M. M. B. Otten

OC-MO-015
8:30 AM - 8:45 AM
CHRONIC WARFARIN USE AND INCIDENT CANCER: A POPULATIONBASED STUDY
V. Pengo* (IT), F. Noventa, U. Gallo, A. Grion, G. Denas, S. Padayattil, P. Prandoni

OC-MO-016
8:45 AM - 9:00 AM
RISK FACTORS FOR RECURRENT THROMBOSIS AND ANTICOAGULANT-RELATED BLEEDING IN CANCER PATIENTS
A. Y. Lee* (CA), S. Parpia, J. Julian, F. Rickles, M. Prins, M. Levine

OC-MO-017
9:00 AM - 9:15 AM
THE EFFECT OF LOW MOLECULAR WEIGHT HEPARIN DALTEPARIN IN NEWLY DIAGNOSED OVARIAN CANCER: A PHASE II RANDOMIZED STUDY A.
Y. Lee* (CA), L. Elit, J. Julian, P. Hoskins, D. Julian, S. Parpia, M. Levine

OC-MO-018
9:15 AM - 9:30 AM
PREVENTION OF THROMBOEMBOLIC EVENTS IN ADVANCED LUNG CANCER PATIENTS RECEIVING CHEMOTHERAPY: A COMBINED ANALYSIS FROM PROTECHT AND TOPIC-2 STUDIES
M. Verso* (IT), G. Agnelli, G. Gussoni

Chairpersons: Pierre Morange (FR) and Astrid van Hylckama (NL)

OC-MO-019
8:00 AM - 8:15 AM
PROTEIN S DEFICIENCY IN A LARGE PANEL OF SMALL THROMBOPHILIA FAMILIES (GIFT STUDY)
M. C. Pintao, J. Veth, R. van Minkelen, H. L. Vos, P. H. Reitsma, R. M. Bertina, M. C. H. de Visser* (NL)

OC-MO-020
8:15 AM - 8:30 AM
SINGLE NUCLEOTIDE POLYMORPHISMS IN AKT3 ARE ASSOCIATED WITH DEEP VEIN THROMBOSIS
L. A. Bare* (US), I. D. Bezemer, A. R. Arellano, C. H. Tong, P. H. Reitsma, J. J. Devlin, F. R. Rosendaal

OC-MO-021
8:30 AM - 8:45 AM
A MULTI-STAGE / MULTI-DESIGN STRATEGY IDENTIFIES A NEW QTL FOR VON WILLEBRAND FACTOR ON CHROMOSOME 6–A POSSIBLE LINK WITH VTE?
G. Antoni* (FR), N. Saut, Y. Luo, G. Burgos, S. Heath, C. Perret, M. Desuremain, C. Biron-Andreani, J. Schved, G. Pernod, P. Galan, D. Zelenika, I. Juhan-Vague, M. Alessi, L. Drouet, S. Visvikis-Siest, M. Lathrop, P. S. Wells, J. Emmerich, F. Gagnon, P. Morange, D. Tregouet

OC-MO-022
8:45 AM - 9:00 AM
FIBRINOGEN MUTATIONS SPECIFIC TO CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION T.
A. Morris* (US), J. J. Marsh, P. G. Chiles, N. Liang, V. L. Woods

OC-MO-023
9:00 AM - 9:15 AM
GENETIC VARIATIONS AND ELEVATED LEVELS OF FIBRINOGEN AND THE RISK OF VENOUS THROMBOSIS
A. van Hylckama Vlieg* (NL), R. G. J. van der Voort, C. J. M. Doggen, F. R. Rosendaal

OC-MO-024
9:15 AM - 9:30 AM
GENE DISCOVERY FOR VENOUS THROMBOSIS IN A LARGE PROTEIN C DEFICIENT FAMILY
C. Y. Vossen* (NL), S. J. Hasstedt, P. W. Callas, C. C. Elbers, B. P. C. Koeleman, F. R. Rosendaal, E. G. Bovill

Chairpersons: Armando Tripodi (IT) and Vittorio Pengo (IT)

OC-MO-025
8:00 AM - 8:15 AM
TISSUE FACTOR ACTIVITY IN MONOCYTES OF WHOLE BLOOD INDUCED BY LUPUS ANTICOAGULANT - A POSSIBLE RISK FACTOR FOR THROMBOSIS
D. T. Le, D. Ho, J. O. Olsen, B. Østerud* (NO)

OC-MO-026
8:15 AM - 8:30 AM
PATHOGENIC EFFECTS OF ANTIPHOSPHOLIPID (APL) ANTIBODIES (ABS) ARE AMELIORATED IN ANNEXIN A2 DEFICIENT MICE S.
S. Pierangeli* (US), Z. Romay- Penabad, G. Montiel-Manzano, T. Shilagard, E. Papalardo, G. Vargas, K. Hajjar

OC-MO-027
8:30 AM - 8:45 AM
HIGH LEVELS OF SERUM IMMUNOGLOBULIN G PREDICT THE RISK OF THROMBOSIS IN PATIENTS WITH THE LUPUS ANTICOAGULANT (LAC)
R. Vormittag* (AT), S. Panzer, C. Ay, P. Quehenberger, S. Koder, I. Pabinger

OC-MO-028
8:45 AM - 9:00 AM
LONG-TERM CLINICAL COURSE OF PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME (APS) AND TRIPLE POSITIVE LABORATORY TESTS
V. Pengo* (IT), C. Legnani, F. Marongiu, P. Gresele, S. Testa, G. Denas, E. Bison, A. Banzato, S. Padayattil, D. Barcellona, A. Ruffatti

OC-MO-029
9:00 AM - 9:15 AM
THE RISK OF HEART VALVE DISEASE ASSOCIATED WITH ANTIPHOSPHOLIPID ANTIBODIES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A META-ANALYSIS OF ECHOCARDIOGRAPHIC STUDIES
S. Zuily* (FR), P. Dotto, C. Perret-Guillaume, E. Bodé-Dotto, E. de Maistre, C. Selton-Suty, J. Bruntz, V. Regnault, T. Lecompte, D. Wahl

OC-MO-030
9:15 AM - 9:30 AM
A RAPID ASSAY TO DISTINGUISH BETWEEN BETA2-GLYCOPROTEIN I DEPENDENT AND PROTHROMBIN DEPENDENT LUPUS ANTICOAGULANT
G. M. A. van Os* (NL), J. C. M. Meijers, R. T. Urbanus, R. H. W. M. Derksen, P. G. de Groot

Chairpersons: Jorgen Ingerslev (DK) and Thomas Abshire (US)

OC-MO-031
8:00 AM - 8:15 AM
FVIII PRODUCTION AFTER TRANSPLANTATION OF A HEMOPHILIA DONOR LIVER INTO A NORMAL RECIPIENT
C. L. Madeira, R. Layman, M. E. Devera, P. A. Fontes, M. V. Ragni* (US)

OC-MO-032
8:15 AM - 8:30 AM
DETECTION OF PRPSC IN THE SPLEEN OF AN ADULT HAEMOPHILIC PATIENT IN THE UK
J. W. Ironside* (UK), A. Peden, M. W. Head, D. M. Keeling, C. M. Millar, F. G. H. Hill

OC-MO-033
8:30 AM - 8:45 AM
EXTENT OF EXPOSURE TO AND RISK STRATIFICATION OF UK PATIENTS REATED WITH PLASMA CONCENTRATES WITH CONTRIBUTION FROM A DONOR WHO DEVELOPED VCJD F. G. H. Hill* (UK),
A. Zaman, N. Connor, C. Millar, J. Ironside, N. Gill

OC-MO-034
8:45 AM - 9:00 AM
PRIMARY AND SECONDARY PROPHYLAXIS IN CHILDREN WITH HAEMOPHILIA A REDUCES BLEEDING FREQUENCY AND ARTHROPATHY DEVELOPMENT COMPARED TO ON-DEMAND TREATMENT: A 10-YEAR, RANDOMIZED, CLINICAL TRIAL
A. Gringeri* (IT), B. Lundin, S. von Mackensen, L. G. Mantovani, P. M. Mannucci

OC-MO-035
9:00 AM - 9:15 AM
PLASMA DERIVED (PD) AND RECOMBINANT (R) FACTOR VIII (FVIII) CONCENTRATES INDUCE A DIFFERENT RATE OF INHIBITOR DEVELOPMENT IN HEMOPHILIA A PATIENTS. A SYSTEMATIC REVIEW OF THE LITERATURE
A. Iorio* (IT), M. Marcucci, E. Marchesini, P. Mannucci

OC-MO-036
9:15 AM - 9:30 AM
A CASE-CONTROLLED DANISH-RUSSIAN COMPARATIVE STUDY OF CLINICAL OUTCOMES IN YOUNGER SEVERE HAEMOPHILIA PATIENTS TREATED WITH PROPHYLAXIS COMPARED TO THOSE MANAGED WITH ON-DEMAND TREATMENT
J. Ingerslev* (DK), S. Lethagen, L. Hvitfeldt Poulsen, E. Lopatina, I. Tentsova, O. Yastrubinetskaya, O. P. Plyushch

Chairpersons: Menno Huisman (NL) and Marc Righini (CH)

OC-MO-037
8:00 AM - 8:15 AM
THE SAFETY OF EXCLUDING ACUTE PULMONARY EMBOLISM BASED ON AN UNLIKELY CLINICAL PROBABILITY BY THE WELLS RULE AND A NORMAL D-DIMER CONCENTRATION
F. A. Klok* (NL), J. D. Snoep, S. M. Pasha, I. C. M. Mos, S. Siragusa, R. J. Goekoop, M. A. Rodger, M. V. Huisman

OC-MO-038
8:15 AM - 8:30 AM
COMPARISON OF THE UNSTRUCTURED CLINICIAN GESTALT, THE WELLS SCORE AND THE REVISED GENEVA SCORE TO ESTIMATE THE PRETEST PROBABILITY FOR SUSPECTED PULMONARY EMBOLISM
P. Roy* (FR), C. Coroller-Bec, S. Dambrine, M. Righini, J. Callahan, A. Perrier, H. Bounameaux, G. Le Gal

OC-MO-039
8:30 AM - 8:45 AM
IMPLEMENTATION OF A DECISION RULE AND A D-DIMER ASSAY IN THE DIAGNOSIS OF PULMONARY EMBOLISM N. S. Gibson* (NL), R. A. Douma, M. Sohne, A. Squizzqato, H. R. Buller, V. E. A. Gerdes

OC-MO-040
8:45 AM - 9:00 AM
DETECTION OF PULMONARY EMBOLISM WITH PULMONARY MDCTANGIOGRAPHY OR VENTILATION/PERFUSION SPECT COMBINED WITH LOW-DOSE CT
J. Mortensen* (DK), H. Gutte, C. V. Jensen, P. V. D. Recke, C. L. Petersen, J. Kjærgaard, U. S. Kristoffersen, A. Kjær

OC-MO-041
9:00 AM - 9:15 AM
COMPLETE VENOUS ULTRASOUND IN OUTPATIENTS WITH SUSPECTED PULMONARY EMBOLISM
M. Righini* (CH), G. Le Gal, D. Aujesky, P. Roy, O. Sanchez, F. Verschurren, L. Bressollette, G. Meyer, A. Perrier, H. Bounameaux

OC-MO-042
9:15 AM - 9:30 AM
D-DIMER AND CLINICAL PROBABILITY TO RULE OUT PULMONARY EMBOLISM IN CANCER PATIENTS: AN EXPLORATIVE STUDY TO INCREASE THE CLINICAL UTILITY
G. L. van Sluis* (NL), R. A. Douma, M. Sohne, P. W. Kamphuisen, F. W. G. Leebeek, H. R. Buller

Chairpersons: Wolfgang Bergmeier (US) and Jonathan N. Thon (US)

OC-MO-043
8:00 AM - 8:15 AM
OSTEOACTIVIN POSITIVELY REGULATES PLATELET FUNCTIONTHROUGH INTEGRIN-MEDIATED SIGNALING
S. Kim* (US), J. Belcher, B. Nagy Jr, K. Bhavaraju, F. F. Safadi

OC-MO-044
8:15 AM - 8:30 AM
HUMAN GAS6 CONTRIBUTES TO LATE INTEGRIN ALPHAIIBBETA3 ACTIVATION AND THROMBUS STABILIZATION: INVOLVEMENT OF AKT
J. M. E. M. Cosemans* (NL), I. C. A. Munnix, L. J. Schurgers, A. Angelillo-Scherrer, M. F. Hoylaerts, P. Carmeliet, J. W. M. Heemskerk

OC-MO-045
8:30 AM - 8:45 AM
ANTAGONISTS OF INTEGRIN GPIIB/IIIA PARADOXICALLY ENHANCE GPVI-INDUCED PLATELET ACTIVATION, REVEALING A FEEDBACK SIGNALLING PATHWAY FROM INTEGRIN TO GPVI INVOLVING THE PROTEIN TYROSINE PHOSPHATASE PTP1B
M. L. Jones* (UK), M. T. Harper, E. W. Aitken, A. W. Poole

OC-MO-046
8:45 AM - 9:00 AM
JUNCTIONAL ADHESION MOLECULE-A NEGATIVELY REGULATES INTEGRIN ALPHA IIB BETA 3-DEPENDENT CONTRACTILE SIGNALING IN PLATELETS
U. P. Naik* (US), M. U. Naik

OC-MO-047
9:00 AM - 9:15 AM
THE MIGFILIN-FILAMIN INTERACTION REGULATES INTEGRIN ACTIVATION
M. Das* (US), S. Ithychanda, J. Qin, E. F. Plow

OC-MO-048
9:15 AM - 9:30 AM
INTERACTIONS OF KINDLIN-2 AND TALIN WITH INTEGRIN BETA CYTOPLASMIC TAILS
K. Bledzka* (US), Y. Q. Ma, J. Qin, E. F. Plow

Chairpersons: Patrick Mismetti (FR) and Alex Spyropoulos (US)

OC-MO-049
8:00 AM - 8:15 AM
A RISK ASSESSMENT MODEL FOR THE IDENTIFICATION OF HOSPITALIZED MEDICAL PATIENTS AT RISK OF VENOUS THROMBOEMBOLISM
S. Barbar, D. Tormene, M. Perlati, B. Brandolin, P. Simioni, A. Pagnan, P. Prandoni* (IT)

OC-MO-050
8:15 AM - 8:30 AM
BIOLOGICAL AND CLINICAL PREDICTORS OF BLEEDING IN 999 PATIENTS TREATED WITH FONDAPARINUX AFTER MAJOR ORTHOPAEDIC SURGERY: THE POP-A-RIX STUDY FROM THE GETHCAM INVESTIGATORS
P. Mismetti* (FR), E. Presles, X. Delavenne, P. Zufferey, J. Barré, P. Nguyen, J. Borg, N. Rosencher, S. Laporte

OC-MO-051
8:30 AM - 8:45 AM
ALIGNMENT TO PROPHYLAXIS GUIDELINES ANDOCCURRENCE OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP AND KNEE REPLACEMENT
R. Selby* (CA), B. Borah, H. McDonald, J. Henk, M. Crowther, P. Wells

OC-MO-052
8:45 AM - 9:00 AM
VENOUS THROMBOEMBOLISM RISK FACTORS IN ACUTELY ILL HOSPITALIZED MEDICAL PATIENTS: FINDINGS FROM THE IMPROVE REGISTRY
A. C. Spyropoulos* (US), F. A. Anderson, G. Fitzgerald, H. Decousus, V. Tapson

OC-MO-053
9:00 AM - 9:15 AM
PREDICTORS OF VENOUS THROMBOEMBOLISM (VTE) AND BLEEDING IN 3600 ACUTELY ILL MEDICAL PATIENTS RECEIVING THROMBOPROPHYLAXIS
S. Laporte* (FR), G. F. Pineo, C. Chapelle, J. Liotier, F. Kleber, P. Mismetti

OC-MO-054
9:15 AM - 9:30 AM
IMPACT OF AGE, BODY MASS INDEX, AND RENAL IMPAIRMENT ON VENOUS THROMBOEMBOLISM RISK AND PROPHYLAXIS PRACTICES IN THE ACUTE HOSPITAL CARE SETTING: A SUBANALYSIS OF THE ENDORSE SURVEY
F. Anderson* (US), A. Cohen, V. Tapson, J. Bergmann, S. Goldhaber, A. Kakkar

Chairpersons: Bjarne Østerud(NO)and Christian Furlan-Freguia (US)

OC-MO-055
8:00 AM - 8:15 AM
ZINC-CONTAINING PROTEIN S INHIBITS EXTRINSIC FACTOR X ACTIVATING COMPLEX INDEPENDENTLY OF TISSUE FACTOR PATHWAY INHIBITOR
N. L. Fernandes* (US), M. J. Heeb

OC-MO-056
8:15 AM - 8:30 AM
REDOX PROPERTIES OF THE TISSUE FACTOR MEMBRANE-PROXIMAL DISULFIDE BOND
T. M. Brophy* (AU), H. H. P. Liang, P. J. Hogg

OC-MO-057
8:30 AM - 8:45 AM
BETA3 INTEGRINS ARE REQUIRED FOR THE ACCUMULATION OF EXTRACELLULAR PROTEIN DISULFIDE ISOMERASE FOLLOWING LASER-INDUCED VASCULAR INJURY IN LIVE MICE
J. Cho* (US), D. R. Kennedy, G. Merrill-Skoloff, B. C. Furie, B. Furie

OC-MO-058
8:45 AM - 9:00 AM
ELIMINATION OF HUMAN RECOMBINANT MAMMALIAN TISSUE FACTOR PATHWAY INHIBITOR IN A RAT MODEL
C. Øie* (NO), E. Brodin, I. Hilden, R. Appa, B. Smedsrød, J. B. Hansen

OC-MO-059
9:00 AM - 9:15 AM
FACTOR VII RETAINS FUNCTION WHEN FUSED TO ALBUMIN OR ANNEXIN V VIA A REPEATED ACTIVATION SITE
A. Puchta* (CA), B. J. Clarke, W. P. Sheffield

OC-MO-060
9:15 AM - 9:30 AM
TWO RESIDUES IN THE ACTIVATION PEPTIDE OF FACTOR X DETERMINE ITS HALF-LIFE IN VIVO
P. Gueguen, I. Badirou, G. Cherel, R. Pendu, C. V. Denis, O. D. Christophe* (FR)

Chairpersons: Koen Mertens (NL) and Laurent Burnier (CH)

OC-MO-061
8:00 AM - 8:15 AM
FUNCTIONAL DIFFERENCES BETWEEN HUMAN AND BOVINE PROTHROMBINASE IN THE ACTIVATION OF PRETHROMBIN-1 CAN BE ATTRIBUTED TO THE COOH-TERMINUS OF FACTOR Va HEAVY CHAIN
P. Y. Kim* (CA), R. Manuel, M. E. Nesheim

OC-MO-062
8:15 AM - 8:30 AM
ACTIVATED FACTOR X CLEAVES FACTOR VIII AT ARGININE 562 LIMITING ITS COFACTOR EFFICIENCY
J. Plantier* (FR), V. Rolli, C. Ducasse, Y. Dargaud, N. Enjolras, H. Boukerche, C. Négrier

OC-MO-063
8:30 AM - 8:45 AM
NOVEL APC-MEDIATED CLEAVAGE SITES FOUND IN THE HEAVY CHAIN OF COAGULATION FACTOR Va
S. Tran* (SE), B. Dahlback

OC-MO-064
8:45 AM - 9:00 AM
REDUCTION OF THE ANTI-FACTOR VIII HUMORAL IMMUNE RESPONSE IN FACTOR VIII-DEFICIENT MICE FOLLOWING MATERNO-FETAL TRANSFER OF ANTI-FACTOR VIII IGG
Y. Meslier* (FR), S. André, M. Teyssandier, S. V. Kaveri, S. Lacroix-Desmazes

OC-MO-065
9:00 AM - 9:15 AM
THE ROLE OF N- LINKED GLYCANS IN THE EXPRESSION AND INTRACELLULAR PROCESSING OF VWF
T.A. J. McKinnon* (UK), A. C. K. Chion, G. Birdsey, M. A. Laffan

OC-MO-066
9:15 AM - 9:30 AM
THE ACTIVATED PLATELET MEMBRANE DIRECTS PROTHROMBIN ACTIVATION THROUGH A PATHWAY DISTINCT FROM THAT ON PHOSPHOLIPID VESICLES
J. P. Wood* (US), J. R. Silveira, P. B. Tracy

Chairpersons: Meghna Naik (US) and Magdalena Chrzanowska-Wolnicka (US)

OC-MO-067
8:00 AM - 8:15 AM
ROLE OF THE SMALL GTPASE RAB27A IN EXOCYTOSIS OF WEIBELPALADE BODIES FROM ENDOTHELIAL CELLS
R. Bierings* (UK), B. Patel, L. Knipe, L. Hewlett, T. Carter, M. J. Hannah

OC-MO-068
8:15 AM - 8:30 AM
DIFFERENTIAL VASP PHOSPHORYLATION CONTROLS ACTIN CYTOSKELETON REMODELING
S. Seifert* (DE), P. M. Benz, C. Blume, S. Wilhelm, J. Waschke, K. Schuh, T. Muenzel, F. B. Gertler, T. Renné

OC-MO-069
8:30 AM - 8:45 AM
A ROLE FOR THE ENDOTHELIAL TETRASPANIN TSPAN18 IN CALCIUM SIGNALLING
D. Colombo, V. L. Heath, J. M. J. Herbert, R. Bicknell, S. P. Watson, M. G. Tomlinson* (UK)

OC-MO-070
8:45 AM - 9:00 AM
PHOSPHOLIPASE D, BUT NOT CALCIUM OR CYCLIC AMP, IS REQUIRED FOR REGULATED SECRETION OF VWF INDUCED BY B5 SUBUNITS OF SHIGA-LIKE TOXIN TYPE 2 J. Huang* (US), F. Liu, E. Sadler

OC-MO-071
9:00 AM - 9:15 AM
JAM-A NEGATIVELY REGULATES VASCULAR PERMEABILITY: ENHANCED VASCULAR PERMEABILITY IN JAM-A NULL MICE IS VEGF-DEPENDENT M. U. Naik* (US), U. P. Naik

OC-MO-072
9:15 AM - 9:30 AM
ANTI-DENGUE NS1 ANTIBODY INDUCES HEME OXYGENASE1 GENE EXPRESSION IN ENDOTHELIAL CELLS P. Rahayu, S. Naidu, A. Rachman, S. Immenschuh, S. Santoso* (DE)

Chairpersons: Susan Lord (US) and Rustem Litvinov (US)

OC-MO-073
8:00 AM - 8:15 AM
THE PROCOAGULANT PHENOTYPE OF THE CELL DICTATES FIBRIN CLOT STRUCTURE R. A. Campbell* (US),
K. A. Overmyer, A. S. Wolberg

OC-MO-074
8:15 AM - 8:30 AM
SELECTIVE DETECTION OF FREE PLASMIN USING A CHROMOGENIC SUBSTRATE BOUND TO AGAROSE BEADS
T. A. Mewhort-Buist* (CA), L. R. Berry, A. K. C. Chan

OC-MO-075
8:30 AM - 8:45 AM
KINETICS OF FIBRIN DISSOLUTION INITIATED BY PLASMINOGEN ACTIVATION IN FIBRIN MATRICES OF VARYING ARCHITECTURE
C. Longstaff* (UK), L. Szabó, K. Kolev

OC-MO-076
8:45 AM - 9:00 AM
POLYPHOSPHATE MODIFIES FIBRIN STRUCTURE AND INCREASES THE RESISTANCE OF CLOTS TO FIBRINOLYSIS
N. J. Mutch* (UK), S. Uitte de Willige, R. Engel, H. Philippou, R. A. S. Ariens

OC-MO-077
9:00 AM - 9:15 AM
INCREASED FIBRIN CLOT FORMATION AND SUSCEPTIBILITY TO THROMBOSIS IN STAT5-DEFICIENT MICE
S. M. Nordstrom* (US), B. C. Sos, T. S. Fong, E. J. Weiss

OC-MO-078
9:15 AM - 9:30 AM
ELEVATED FIBRINOGEN GAMMA’ RATIO IS ASSOCIATED WITH CARDIOVASCULAR DISEASES, BUT NOT WITH ACUTE PHASE REACTION OR CLINICAL OUTCOME
E. Y. Cheung* (NL), H. L. Vos, M. J. Kruip, H. M. den Hertog, P. J. Koudstaal, R. M. Bertina, M. P. de Maat

Chairpersons: Marc Rodger (CA) and Linda Flinterman (NL)

OC-MO-079
4:00 PM - 4:15 PM
MORTALITY AND RECURRENCE AFTER A FIRST VENOUS THROMBOSIS
L. E. Flinterman* (NL), A. van Hylckama Vlieg, S. C. Cannegieter, F. R. Rosendaal

OC-MO-080
4:15 PM - 4:30 PM
RECURRENT VENOUS THROMBOEMBOLISM (RVTE) AFTER SURGERY-ASSOCIATED VTE: COMPARISON WITH RVTE AFTER UNPROVOKED VTE
R. H. White* (US), B. Danielsen

OC-MO-081
4:30 PM - 4:45 PM
THE LONG-TERM CLINICAL COURSE OF CEREBRAL VEIN THROMBOSIS: A PROSPECTIVE COHORT STUDY
I. Martinelli* (IT), P. Bucciarelli, S. Passamonti, T. Battaglioli, P. M. Mannucci

OC-MO-082
4:45 PM - 5:00 PM
POPULATION BASED COHORT STUDY ON THE RISK OF ARTERIAL THROMBOSIS IN SUBJECTS WITH PREVIOUS VENOUS THROMBOSIS
I. M. van Schouwenburg* (NL), B. K. Mahmoodi, R. T. Gansevoort, N. J. G. M. Veeger, M. M. Visser, W. Lijfering, J. van der Meer

Chairpersons: Paul Monahan (US) and Jenny Goudemand (FR)

OC-MO-083
4:00 PM - 4:15 PM
BIOCHEMICAL CHARACTERIZATION OF FACTOR IX-FC MONOMER
G. Toby* (US), R. T. Peters, A. J. Bitonti

OC-MO-084
4:15 PM - 4:30 PM
DOSE RESPONSE AND PROLONGED EFFECT OF 40K PEG-FIX ON BLEEDING IN HEMOPHILIA B MICE
T. Elm* (DK), H. Oestergaard, M. Tranholm

OC-MO-085
4:30 PM - 4:45 PM
THE PHARMACOKINETICS OF A LONG-ACTING FACTOR IX (40K PEG-RFIX) IN MINIPIGS SUGGESTS AT LEAST A ONCE-WEEKLY DOSING REGIME
L. Hansen, H. Ostergaard, M. Tranholm, H. Agersoe* (DK)

OC-MO-086
4:45 PM - 5:00 PM
IB1001, A NEW RECOMBINANT FACTOR IX PREPARATION: INITIAL SAFETY AND CHARACTERIZATION
E. D. Gomperts* (US), M. Lee, T. Nichols, M. Griffith

Chairpersons: Cornelis Kluft (NL) and Catherine Bagot (UK)

OC-MO-087
4:00 PM - 4:15 PM
SHOULD WE CLASSIFY WOMEN WHO DEVELOP VENOUS THROMBOSIS ON ESTROGEN AS HAVING PROVOKED OR UNPROVOKED VENOUS THROMBOEMBOLISM? RESULTS FROM THE REVERSE STUDY
G. Le Gal* (FR), M. Carrier, M. Rodger

OC-MO-088 4:15 PM - 4:30 PM
THROMBIN GENERATION IS INCREASED IN POST MENOPAUSALWOMEN USING HORMONE REPLACEMENT THERAPY ADMINISTERED BY THE ORAL BUT NOT THE TRANSDERMAL ROUTE
C. N. Bagot* (UK), M. S. Marsh, M. Whitehead, R. Sherwood, L. Roberts, R. K. Patel, R. Arya

OC-MO-089
4:30 PM - 4:45 PM
PEAK THROMBIN GENERATION CORRELATES WITH ESTRADIOL LEVELS IN WOMEN WHO USE HORMONE REPLACEMENT THERAPY ADMINISTERED BY THE ORAL BUT NOT THE TRANSDERMAL ROUTE
C. N. Bagot* (UK), M. S. Marsh, M. Whitehead, R. Sherwood, L. Roberts, R. K. Patel, R. Arya

OC-MO-090
4:45 PM - 5:00 PM
THE EFFECT OF MONOPHASIC ORAL CONTRACEPTIVE REGIMENS ON FACTOR VII-ACTIVATING PROTEASE - A RANDOMIZED MULTICENTRE STUDY
J. J. Sidelmann* (DK), S. O. Skouby, C. Kluft, U. Winkler, F. Vitzthum, H. Schwarz, J. Jespersen

Chairpersons: Charles Francis (US) and Francesco Dentali (IT)

OC-MO-091
4:00 PM - 4:15 PM
ASYMPTOMATIC VENOUS THROMBOEMBOLISM IN CANCER PATIENTS: PREVALENCE AND CONSEQUENCE
R. A. Douma* (NL), M. G. M. Kok, L. M. Verberne, P. W. Kamphuisen, H. R. Büller

OC-MO-092
4:15 PM - 4:30 PM
PROGNOSTIC RELEVANCE OF ASYMPTOMATIC VTE IN CANCER PATIENTS
F. Dentali* (IT), J. Vitale, C. Nitti, D. Imberti, C. Becattini, A. Malato, A. Salvi, M. Giorgi Pierfranceschi, G. Agnelli, S. Siragusa, W. Ageno

OC-MO-093
4:30 PM - 4:45 PM
RESIDUAL VEIN THROMBOSIS FOR ASSESSING THE OPTIMAL DURATION OF ANTICOAGULANTS AFTER DEEP VEIN THROMBOSIS OF THE LOWER LIMBS IN CANCER PATIENTS
S. M. Siragusa* (IT)

OC-MO-094
4:45 PM - 5:00 PM
THROMBOTIC DIATHESIS AND VASCULAR RISK FACTORS IN POLYCYTHEMIA VERA: GENDER RELATED DIFFERENCES
L. di Gennaro* (IT), R. Marfisi, R. Marchioli, R. Landolfi

Chairpersons: Guido Tans (NL) and Laurent Mosnier (US)

OC-MO-095
4:00 PM - 4:15 PM
DOWN REGULATION OF PROTHROMBINASE ACTIVITY BY ACTIVATED PROTEIN C MEASURED IN REAL-TIME DURING PROTHROMBIN ACTIVATION P.
Y. Kim* (CA), M. E. Nesheim

OC-MO-096
4:15 PM - 4:30 PM
MOUSE RECOMBINANT PROTEIN C VARIANTS WITH ENHANCED MEMBRANE AFFINITY AND HYPER-ANTICOAGULANT ACTIVITY IN MOUSE PLASMA
M. J. Krisinger* (SE), L. J. Guo, G. Salvagno, G. C. Guidi, G. Lippi, B. Dahlbäck

OC-MO-097
4:30 PM - 4:45 PM
GLA DOMAIN-MUTATED HUMAN PROTEINS C EXHIBIT ENHANCED ANTICOAGULANT ACTIVITY IN THROMBIN GENERATION ASSAY SYSTEM
G. Salvagno* (IT), G. Lippi, M. Franchini, G. Guidi, B. Dahlback

OC-MO-098
4:45 PM - 5:00 PM
GLA-DOMAIN MUTATED ACTIVATED PROTEIN C EXHIBITS ENHANCED ANTICOAGULANT ACTIVITY ON PLATELET SURFACES
E. A. Norstrom* (SE), Y. Sun, B. Dahlback

Chairperson: Athan Kuliopulos (US)

OC-MO-099
4:00 PM - 4:15 PM
THE NEW TYROSINE-KINASE INHIBITOR AND ANTI-CANCER DRUG DASATINIB REVERSIBLY AFFECTS PLATELET ACTIVATION IN VITRO AND IN VIVO
B. Payrastre, M. Gratacap* (FR), V. Martin, M. Valéra, S. Allart, C. Garcia, P. Sié, C. Recher

OC-MO-100
4:15 PM - 4:30 PM
EP3 RECEPTOR BLOCKADE AND PLATELET FUNCTION IN MAN
S. Heptinstall* (UK), S. C. Fox, J. A. May, D. Hermann, D. Streiter, D. Hartman

OC-MO-101
4:30 PM - 4:45 PM
THE LECTIN-LIKE DOMAIN OF THROMBOMODULIN AND GRP78 COMPLEX EXHIBITS NOVEL ANTI-THROMBOTIC PROPERTIES
A. Sharma* (AU), X. Zhang, A. Samudra, S. Dezfouli, C. Selan, B. Michell, B. Kemp, A. D’Apice, P. Cowan, H. Nandurkar

OC-MO-102
4:45 PM - 5:00 PM
THE MECHANISM OF IVIG TREATMENT FOR IMMUNE-MEDIATED PLATELET DESTRUCTION IS THROUGH INDUCTION OF INTERLEUKIN-11
D. Leontyev* (CA), Y. Katsman, D. R. Branch

Chairpersons: Uri Seligsohn (US) and Coen Maas (NL)

OC-MO-103
4:00 PM - 4:15 PM
STRUCTURAL ANALYSIS OF APPLE DOMAIN MISSENSE MUTATIONS RELATED TO FACTOR XI DEFICIENCY
P. A. McEwan, D. V. Kravtsov, M. Sun, D. Gailani, J. Emsley* (UK)

OC-MO-104
4:15 PM - 4:30 PM
FACTOR XI ACTIVATION IN PLASMA IN THE ABSENCE OF FACTOR XIIA
D. Gailani* (US), A. Matafonov, D. V. Kravtsov, E. I. Tucker, M. Sun, A. Gruber

OC-MO-105
4:30 PM - 4:45 PM
DIMERIZATION OF HUMAN FACTOR XI IS NOT A PREREQUISITE FOR ITS SECRETION OR ACTIVATION
M. Zucker* (IL), A. Zivelin, M. Landau, N. Rosenberg, U. Seligsohn

OC-MO-106
4:45 PM - 5:00 PM
REGULATION OF CONTACT ACTIVATION BY ANTITHROMBIN (AT) AND C1 INHIBITOR (C1INH)
J. Bäck* (SE), G. Elgue, J. Sanchez, K. Nilsson Ekdahl, B. Nilsson

Chairpersons: Yukio Ozaki (JP) and Timothy J. Stalker (US)

OC-MO-107
4:00 PM - 4:15 PM
VAV GUANINE NUCLEOTIDE EXCHANGE FACTORS LINK HYPERLIPIDEMIA AND A PROTHROMBOTIC STATE
K. Chen* (US), W. Li, M. Febbraio, R. Silverstein

OC-MO-108
4:15 PM - 4:30 PM
ROLE OF PDI IN THROMBUS FORMATION IN A COLLAGEN INDUCED PATHWAY
L. Bellido-Martin* (US), G. Merrill-Skoloff, B. Furie, B. C. Furie

OC-MO-109
4:30 PM - 4:45 PM
PLATELET GPIB SENSES ENVIRONMENTAL CONDITIONS AND MODULATES 14-3-3 AVAILABILITY AND OUTSIDE-IN SIGNALS ACROSS ALPHAIIBBETA3 ACCORDINGLY
J. E. B. Fox* (US), Y. Zhang, K. Bialkowska

OC-MO-110
4:45 PM - 5:00 PM
PATHOLOGICAL SHEAR RATES INCREASE LEVELS OF PLATELET RECEPTOR SHEDDING
M. Al-Tamimi* (AU), J. R. Hamilton, S. P. Jackson, A. Ludwig, M. C. Berndt, R. K. Andrews, E. E. Gardiner

Chairpersons: Philip de Groot (NL) and Bas de Laat (NL)

OC-MO-111
4:00 PM - 4:15 PM
PATIENT-DERIVED MONOCLONAL ANTIBODIES DIRECTED TOWARDS DOMAIN I OF BETA2-GLYCOPROTEIN I DISPLAY LAC ACTIVITY
M. Boon-Spijker, I. Dienava* (NL), P. de Groot, J. Voorberg, K. Mertens, B. de Laat, R. Derksen

OC-MO-112
4:15 PM - 4:30 PM
IMMUNE RESPONSES AGAINST DOMAIN I OF BETA2GPI ARE DEPENDENT ON PROTEIN CONFORMATION
B. de Laat* (NL), C. Zappelli, M. van Berkel, B. Siregar, P. de Groot, K. Mertens, M. Gebbink, C. Maas

OC-MO-113
4:30 PM - 4:45 PM
SYNTHESIS, CHARACTERIZATION AND ANTIBODY-BINDING PROPERTIES OF DOMAIN I (1-64) OF BETA2-GLYCOPROTEIN I: IMPLICATION FOR THE ANTIPHOSPHOLIPID SYNDROME (APS)
N. Pozzi* (IT), A. Banzato, E. Bison, S. Olivieri, A. Ruffatti, V. Pengo, V. de Filippis

OC-MO-114
4:45 PM - 5:00 PM
IN VIVO INVOLVEMENT OF APOLIPOPROTEIN E RECEPTOR (APOER2’) ON THROMBOGENIC EFFECTS OF A DIMER OF BETA2GLYCOPROTEIN I (BETA2GPI) AND OF ANTIPHOSPHOLIPID (APL) ANTIBODIES
Z. Romay-Penabad, R. Urbanus, M. Pennings, E. Papalardo, G. Vargas, T. Shilagard, R. Derksen, P. de Groot, S. S. Pierangeli* (US)

Chairpersons: John Weisel (US) and Oleg Gorkun (US)

OC-MO-115
4:00 PM - 4:15 PM
THE ROLE OF THE FIBRINOGEN ALPHA CHAIN IN ENHANCING FXIII ACTIVATION
K. A. Smith* (UK), P. J. Adamson, R. J. Pease, A. J. Balmforth, R. A. S. Ariens, H. Philippou, P. J. Grant

OC-MO-116
4:15 PM - 4:30 PM
THE RELATIVE IMPORTANCE OF FINGER AND KRINGLE DOMAINS IN THE REGULATION OF TPA ACTIVITY
S. Williams* (UK), C. Thelwell, C. Longstaff

OC-MO-117
4:30 PM - 4:45 PM
PLASMIN-CATALYZED LYSIS IS ENHANCED IN FIBRIN VARIANTS WITH WEAKENED HOLE “B”
B. A. Holliday* (US), S. R. Bowley, S. T. Lord

OC-MO-118
4:45 PM - 5:00 PM
COAGULATION FACTOR Xa DERIVATIVE, Xa33/13, ENHANCES PLASMINOGEN ACTIVATION AND CLOT LYSIS
K. Talbot, S. C. Meixner, E. L. G. Pryzdial* (CA)

Chairpersons: Francesco Bernardi (IT) and Beth Bouchard (US)

OC-MO-119
4:00 PM - 4:15 PM
THROMBIN GENERATION IN PATIENTS WITH SEVERE FACTOR V DEFICIENCY RELIES ON PLATELET FACTOR V
C. Duckers* (NL), P. Simioni, C. Radu, L. Spiezia, S. Gavasso, J. Rosing, E. Castoldi

OC-MO-120
4:15 PM - 4:30 PM
THE PLATELET FACTOR V/Va POOL REMAINING TWO WEEKS SUBSEQUENT TO FFP ADMINISTRATION CORRECTS TOTAL PLASMA FACTOR V DEFICIENCY
B. A. Bouchard* (US), K. E. Brummel-Ziedins, J. P. Wood, P. B. Tracy

OC-MO-121
4:30 PM - 4:45 PM
DIRECT CORRELATION BETWEEN PLATELET AND PLASMA FACTOR V LEVELS IN HOMOZYGOUS AND HETEROZYGOUS FACTOR V DEFICIENT SUBJECTS
L. Spiezia* (IT), C. Radu, G. Tognin, C. Bulato, M. Florean, P. Pradella, S. Gavasso, G. Barillari, V. de Angelis, P. Simioni

OC-MO-122
4:45 PM - 5:00 PM
A DATABASE OF MUTATIONS AND POLYMORPHISMS IN AND AROUND THE FACTOR V GENE; AN UPDATE
H. L. Vos* (NL)

Chairpersons: Armin J. Reininger (DE) and Julian I. Borissoff (NL)

OC-MO-123
4:00 PM - 4:15 PM
NON-INVASIVE IDENTIFICATION OF ATHEROSCLERTOTIC PLAQUES VIA TARGETED MOLECULAR IMAGING OF ACTIVATED VON WILLEBRAND FACTOR
R. B. Conley* (US), W. Shentu, A. Xie, Y. Qi, Y. Zhao, C. Carr, T. Belcik, P. G. de Groot, J. R. Lindner, O. McCarty

OC-MO-124
4:15 PM - 4:30 PM
THE INITIAL STEPS OF THROMBUS FORMATION INDUCED BY HUMAN ATHEROSCLEROTIC PLAQUES
A. J. Reininger* (DE), I. Bernlochner, S. Penz, C. Ravanat, P. Smethurst, R. Farndale, C. Gachet, R. Brandl, W. Siess

OC-MO-125
4:30 PM - 4:45 PM
THE PROTHROMBOTIC STATE OF ATHEROSCLEROTIC LESIONS: A POSSIBLE ROLE FOR FXII
J. I. Borissoff* (NL), S. Heeneman, P. Kassak, R. van Oerle, K. Hamulyák, M. Daemen, H. ten Cate, H. Spronk

OC-MO-126
4:45 PM - 5:00 PM
MONOCYTE HETEROGENEITY IN OBESITY AND SUBCLINICAL ATHEROSCLEROSIS G. H. Heine* (DE), K. S. Rogacev, C. Ulrich, L. Blömer, K. Oster, M. Ziegelin, Y. Grenner, J. Geisel, A. Schlitt, H. Köhler, M. Girndt, D. Flliser

Chairpersons: Tatiana Byzkova (US) and Mieke Delvaeya (NL)

OC-MO-127
4:00 PM - 4:15 PM
THROMBOMODULIN OVER-EXPRESSION PREVENT VENOUS THROMBOSIS AND PROLONGS CARDIAC XENOGRAFT SURVIVAL
X. Zhang* (AU), S. Crikis, S. Dezfouli, K. Dwyer, L. Murray-Segal, E. Salvaris, S. Robson, A. D’Apice, P. Cowan, H. Nandurkar

OC-MO-128
4:15 PM - 4:30 PM
PROLYLCARBOXYPEPTIDASE MURINE HYPOMORPHS ARE HYPERTENSIVE AND PROTHROMBOTIC
G. N. Adams* (US), Y. Zhou, G. Larusch, M. Nieman, B. Hoit, G. Jacobs, X. Yu, F. Mahdi, Z. Shariat-Madar, L. D’Alecy, Y. Okada, A. H. Schmaier

OC-MO-129
4:30 PM - 4:45 PM
DIFFERENTIAL EXPRESSION AND SECRETION OF TISSUE FACTOR AND TISSUE FACTOR PATHWAY INHIBITOR MODULATE ENDOTHELIAL THROMBORESISTANCE IN VITRO
J. Madon, W. Ruf, S. Valsami, M. Leikauf, A. Kaech, L. M. Asmis* (CH)

OC-MO-130
4:45 PM - 5:00 PM
MATRIX METALLOPROTEINASE-10 (MMP-10) IS UP-REGULATED BY THROMBIN IN ENDOTHELIAL CELLS AND INCREASED IN PATIENTS WITH ENHANCED THROMBIN GENERATION
J. Orbe* (ES), J. A. Rodriguez, C. Rodriguez, S. Martinez de Lizarrondo, J. Barrenetxe, J. Martinez-Gonzalez, J. C. Reverter, J. A. Paramo

Chairpersons: Jane Freedman (US) and David Varon (IL)

OC-MO-131
4:00 PM - 4:15 PM
IDENTIFICATION OF TWO NOVEL P2Y12 ADP RECEPTOR GENE DEFECTS IN PATIENTS WITH TYPE 1 VON WILLEBRAND DISEASE
M. E. Daly* (UK), B. B. Dawood, W. A. Lester, A. B. Federici, A. Artoni, I. R. Peake, A. D. Mumford, S. P. Watson, S. J. Mundell, on behalf of the EU-VWD Study Group

OC-MO-132
4:15 PM - 4:30 PM
REPRODUCIBILITY OVER TIME OF PLATELET FUNCTION TESTS TO EVALUATE ASPIRIN AND CLOPIDOGREL RESPONSIVENESS: INSIGHT FROM THE ADRIE STUDY ON STABLE CARDIOVASCULAR PATIENTS
J. L. Reny* (FR), I. Barazer, C. Castelli, S. Nolli, P. Berdague, P. Fabbro-Peray, J. Schved, H. Bounameaux, F. Mach, P. de Moerloose, P. Fontana

OC-MO-133
4:30 PM - 4:45 PM
COMMON VARIATION IN THE PLATELET RECEPTOR P2RY12 GENE IS ASSOCIATED WITH RESIDUAL ON-CLOPIDOGREL PLATELET REACTIVITY IN PATIENTS UNDERGOING ELECTIVE PCI
G. Rudez* (NL), H. J. Bouman, J. W. van Werkum, F. W. G. Leebeek, A. Kruit, H. J. T. Ruven, J. M. ten Berg, M. P. M. de Maat, C. M. Hackeng

OC-MO-134
4:45 PM - 5:00 PM
THE INTERPRETATION OF LIGHT TRANSMITTANCE PLATELET AGGREGATION IS INCONSISTENT – RESULTS FROM AN INTERNATIONAL CHALLENGE
K. A. Moffat* (CA), E. Plumhoff, E. Reyes, S. Hoffman, S. Israels, P. Meijer, C. P. M. Hayward

OC-MO-135
5:00 PM - 5:15 PM
WHICH PLATELET FUNCTION TEST IS THE MOST SENSITIVE FOR THE IN VIVO EFFECTS OF CLOPIDOGREL? A PHARMACOKINETIC ANALYSIS
H. J. Bouman* (NL), J. W. van Werkum, N. J. Breet, C. M. Hackeng, J. M. ten Berg, D. Taubert

Chairpersons: Ming Hou (CN) and Samuel Machin (UK)

OC-MO-136
4:00 PM - 4:15 PM
THE EFFECT OF BAFF AND BAFF-R-FC FUSION PROTEIN IN CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA
X. Zhu, Y. Shi, J. Sun, J. Peng, C. Guo, P. Qing, X. Zhang* (CN), X. Ji, L. Wang, M. Hou

OC-MO-137
4:15 PM - 4:30 PM
MESENCHYMAL STEM CELL-MODULATED DENDRITIC CELLS INDUCE PLATELET-SPECIFIC T CELL-ANERGY IN IDIOPATHIC THROMBOCYTOPENIC PURPURA X.
Zhang* (CN), J. Peng, Y. Shi, C. Guo, J. Sun, M. Hou

OC-MO-138
4:30 PM - 4:45 PM
THE PHARMACOKINETICS OF RITUXIMAB IN ACUTE IDIOPATHIC THROMBOTIC THROMBOCYTOPENIC PURPURA (AITTP)
V. McDonald* (UK), I. J. Mackie, K. Manns, S. J. Machin, M. A. Scully

OC-MO-139
4:45 PM - 5:00 PM
ROLE OF NEONATAL FC RECEPTOR (FCRN) IN FETAL AND NEONATAL IMMUNE THROMBOCYTOPENIA (FNIT) AND FNIT THERAPY
P. Chen, G. Zhu, J. Freedman, H. Ni* (CA)

Chairperson: Ken Bauer (US)

LB-MO-001
8:00 AM – 8:15 PM
LATE BREAKING CLINICAL TRIAL: A RANDOMISED COMPARISON OF THE QUALITY OF ANTICOAGULANT THERAPY WITH TWO VITAMIN K ANTAGONISTS: WARFARIN VERSUS PHENPROCOUMON
Y. van Leeuwen* (NL), E. P. A. Gebuis, F. J. M. van der Meer, F. R. Rosendaal

LB-MO-002
8:15 AM – 8:30 AM
LATE BREAKING CLINICAL TRIAL: A RANDOMISED DOUBLE BLIND TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PROLONGING THE THROMBOPROPHYLAXIS WITH BEMIPARIN IN PATIENTS UNDERGOING CANCER ABDOMINAL OR PELVIC SURGERY (THE CANBESURE STUDY)
V. V. Kakkar* (UK), J. Balibrea, J. Martinez-Gonzalez, P. Prandoni

LB-MO-003
8:30 AM – 8:45 AM
LATE BREAKING CLINICAL TRIAL: A PROSPECTIVE, RANDOMIZED TRIAL OF CHEMOTHERAPY WITH AND WITHOUT THE LOW MOLECULAR WEIGHT HEPARIN (LMWH) ENOXAPARIN IN ADVANCED PANCREATIC CANCER PATIENTS
H. B. Riess* (DE), U. Pelzer, B. Opitz, A. Hilbig, M. Strauch, S. Hahnfeld, G. Deutschinoff, J. Stieler, P. Reizig, H. Oettle

LB-MO-004
8:45 AM – 9:00 AM
LATE BREAKING CLINICAL TRIAL: THE EFFECT OF THE LOW-MOLECULAR-WEIGHT HEPARIN NADROPARIN ON THE SURVIVAL IN PATIENTS WITH CANCER: A RANDOMIZED TRIAL (FOR THE INPACT INVESTIGATORS)
H. R. Buller*(NL), M. H. Prins

LB-MO-005
9:00 AM – 9:15 AM
LATE BREAKING CLINICAL TRIAL: THE ADVANCE - 2 STUDY: A RANDOMIZED DOUBLE-BLIND TRIAL COMPARING APIXABAN WITH ENOXAPARIN FOR THROMBOPROPHYLAXIS AFTER TOTAL KNEE REPLACEMENT
M. R. Lassen*(DK), A. S. Gallus, G. F. Pineo, G. E. Raskob